Perrigo's Pennsaid equivalent approved by FDA

DUBLIN — Perrigo on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for diclofenac sodium topical solution 1.5% w/w. 

 

The generic equivalent to Pennsaid (diclofenac sodium topical solution) 1.5% w/w, the medicine is indicated for the treatment of signs and symptoms of osteoarthritis of the knee. Brand sales were approximately $38 million for the 12 months before any generic competition, Perrigo reported.

 

"This product approval and launch further strengthens our leading Rx position and highlights our commitment to bringing new affordable products to the market," said Joseph Papa, Perrigo chairman, president and CEO.